- Home
- KRYS vs AB Comparison
KRYS vs AB Comparison
Compare KRYS & AB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRYS
- AB
- Stock Information
- Founded
- KRYS 2015
- AB 1987
- Country
- KRYS United States
- AB United States
- Employees
- KRYS N/A
- AB N/A
- Industry
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- AB Investment Managers
- Sector
- KRYS Health Care
- AB Finance
- Exchange
- KRYS Nasdaq
- AB Nasdaq
- Market Cap
- KRYS 5.1B
- AB 4.4B
- IPO Year
- KRYS 2017
- AB 1988
- Fundamental
- Price
- KRYS $170.21
- AB $36.91
- Analyst Decision
- KRYS Strong Buy
- AB Strong Buy
- Analyst Count
- KRYS 8
- AB 5
- Target Price
- KRYS $199.43
- AB $43.00
- AVG Volume (30 Days)
- KRYS 236.9K
- AB 325.0K
- Earning Date
- KRYS 11-04-2024
- AB 10-24-2024
- Dividend Yield
- KRYS N/A
- AB 8.32%
- EPS Growth
- KRYS N/A
- AB 57.32
- EPS
- KRYS 1.77
- AB 3.49
- Revenue
- KRYS $241,519,000.00
- AB $134,096,000.00
- Revenue This Year
- KRYS $485.65
- AB N/A
- Revenue Next Year
- KRYS $58.64
- AB $7.01
- P/E Ratio
- KRYS $100.04
- AB $10.62
- Revenue Growth
- KRYS 2722.80
- AB N/A
- 52 Week Low
- KRYS $96.73
- AB $27.40
- 52 Week High
- KRYS $219.34
- AB $38.96
- Technical
- Relative Strength Index (RSI)
- KRYS 42.62
- AB 51.15
- Support Level
- KRYS $182.26
- AB $35.55
- Resistance Level
- KRYS $207.84
- AB $37.07
- Average True Range (ATR)
- KRYS 8.55
- AB 0.84
- MACD
- KRYS -0.10
- AB -0.18
- Stochastic Oscillator
- KRYS 20.00
- AB 47.12
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
About AB AllianceBernstein Holding L.P.
AllianceBernstein provides investment management services to institutional (42% of assets under management), retail (41%), and private (17%) clients through products that includes mutual funds, hedge funds, and separately managed accounts. At the end of July 2024, AB had $777 billion in managed assets, composed primarily of fixed-income (37% of AUM) and equity (43%) strategies, with other investments (made up of asset allocation services and certain other alternative investments) accounting for the remainder.